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Edited by Varda RotterAbstract We investigated the role of p53 in nuclear factor
(NF)-jB dependent, platelet-activating factor (PAF)-induced
vascular endothelial growth factor (VEGF) expression. Trans-
fected NF-jB subunits in ECV304 cells increased the tumor
necrosis factor-a promoter activity, which was completely inhib-
ited by p53. Transfected p53 increased p53RE promoter activity,
which was completely inhibited by NF-jB subunits, indicating
that cross-regulation occurs between NF-jB and p53. PAF-
induced increase in VEGF expression was correlated with de-
creased p53 activity. These data suggest that NF-jB-dependency
of the PAF-induced increase in VEGF expression is due to de-
creased p53 activity, which is reciprocally regulated by increased
NF-jB activity.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Neovasculization or angiogenesis is required to sustain
growth of primary tumors and metastases. Tumor angiogene-
sis is mediated by increased production of various angiogenic
molecules released by both the tumor itself and nearby host
cells [1,2]. Vascular endothelial growth factor (VEGF) is a po-
tent peptide growth factor speciﬁc for vascular endothelial cells
that promotes neovascularization and increases vascular per-
meability in vivo [3]. The critical role of VEGF in tumor angi-
ogenesis has been demonstrated as inhibition of tumor growth
following treatment with anti-VEGF neutralizing antibodies
[4] or by administration of VEGF receptor (ﬂk-1) antagonists
[5]. The VEGF promoter contains AP-1, AP-2, SP-1, and HIF-
1 binding sites [6,7]. Hypoxia induces VEGF expression
through activation of HIF-1 [7] and AP-1 [8,9], whereas tumor
necrosis factor (TNF)-a increases VEGF expression via SP-1
[8,10].Abbreviations: PAF, platelet-activating factor; NF-jB, nuclear factor
kappaB; p65 AS, p65 antisense oligonucleotide; p65 NS, p65 non-sense
scrambled oligonucleotide; VEGF, vascular endothelial growth factor
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doi:10.1016/j.febslet.2006.04.042Platelet-activating factor (PAF), which is produced by a
variety of inﬂammatory cells, is a potent lipid messenger in-
volved in cellular activation, fertilization, intracellular signal-
ing, apoptosis, and diverse inﬂammatory reactions [11–14].
We have shown that PAF is a proximal inducer of the tran-
scription factor, nuclear factor (NF)-jB, a pivotal transcrip-
tion factor that regulates the expression of proinﬂammatory
cytokines and many immunoregulatory molecules [15,16] in re-
sponse to inﬂammatory stimuli [17,18] and microbial infection
[19]. Recently, we have shown that PAF promotes angiogene-
sis through the production of NF-jB-dependent angiogenic
factors such as interleukin-1, TNF-a, basic ﬁbroblast growth
factor (bFGF), and VEGF [20]. Other investigators also have
reported that VEGF production and gene expression is com-
promised by NF-jB inhibition [21,22]. However, NF-jB does
not appear to regulate VEGF expression directly, as its pro-
moter does not contain an NF-jB binding site [7].
One mechanism by which NF-jB enhances VEGF expres-
sion is to regulate the expression of genes that directly regulate
its expression. One candidate gene is the tumor suppressor
gene, p53. p53 is one of the most frequently mutated genes
in human cancers [23]. Wild-type p53 protein downregulates
VEGF promoter activity [24], but the loss of p53 function,
via somatic mutations or the expression of viral oncoproteins,
contributes to angiogenesis during tumorigenesis [25–27]. Fur-
thermore, NF-jB and p53 cross-regulate mRNA expression.
For example, p53 activation by daunomycin is partially regu-
lated by NF-jB [28]. Similarly, NF-jB activation increases
p53 promoter activity [29]. In contrast, other groups have
reported that NF-jB activation blocks p53 transactivation
[30–33]. Thus, it is possible that NF-jB upregulates VEGF
expression through modulating p53 activity in PAF-induced
angiogenesis. Thus, we investigated this possibility and found
that a reciprocal regulation between NF-jB and p53 occurred
in PAF-induced VEGF expression.2. Materials and methods
2.1. Reagents
PAF (1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine) was pur-
chased from Sigma Chemical Co. (St. Louis, MO). The PAF receptor
antagonist, WEB2170 was a gift from Dr. Rhee, C.K. (College of Med-
icine, Dankook University, Korea). The NF-jB inhibitor, partheno-
lide was from BIOMOL Research Laboratories Inc. (Plymouth
Meeting, PA, USA). ELISA kit for detecting human VEGF wasblished by Elsevier B.V. All rights reserved.
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and the luciferase assay kit were purchased from Promega (Madison,
WI).
2.2. Antisense oligonucleotides
The following phosphorothioate oligonucleotides were synthesized
for use in antisense inhibition of gene expression (Peptron, Korea):
p65 antisense (p65 AS) of the 5 0 end of the NF-jB gene (5 0-GAAACA-
GATCGTCCATGGT-3 0). A p65 scrambled control (p65 non-sense,
p65NS) oligonucleotide (5 0-GTACTACTCTGAGCAAGGA-3 0) was
synthesized to serve as a negative control. The NF-jB AS or NS oligo-
nucleotide includes the ATG initiation codon.
2.3. Cell culture
ECV304 cells, an immortalized and transformed human vascular
endothelial cell line [34], was maintained in Dulbecco’s modiﬁed Eagle
medium (DMEM, GIBCO, Grand Island, NY) supplemented with
10% fetal bovine serum (FBS, CAMBREX Co., Walkersville, MD)
at 37 C in a 5% CO2 atmosphere. We have already demonstrated that
ECV304 cells are of endothelial origin using immunohistochemistry
[35]. The human colon cancer cell line, DLD-1, was routinely cultured
in RPMI 1640 (GIBCO) supplemented with 10% FBS, 100 U/ml
penicillin, and 100 mg/ml streptomycin.
2.4. Reporter and expression constructs
The AccI-NheI fragment comprising 2018 to +50 bp of the VEGF
promoter (pLuc 2068) was cloned upstream of the promoterless lucifer-
ase reporter vector in pAH 1409 (VEGF-Luc, a gift from Dr. Finkenz-
eller, G., Molecular Medicine Institute, Germany). Human wild-type
p53 and mutant p53 (His175) were cloned in pcDNA3 (a gift from
Dr. Xirodimas, D., Ninewells Hospital & Medical School, UK). cDNA
encoding p65, p50, and IjBa were cloned in pcDNA3. Reporter con-
structs of the p53RE luciferase reporter plasmid (p53RE-Luc) was a gift
fromDr. Lee, J.W. (Baylor College ofMedicine, Houston, TX), and the
TNF-a promoter/luciferase reporter plasmid (TNF-a-Luc) was a gift
from Dr. Lee, H.B. (Chonnam National University, Korea).
2.5. Electrophoretic mobility shift assay
Nuclear extracts were prepared from the cells, as described previ-
ously [17,18]. To inhibit endogenous protease activity, 1 mM phenyl-
methylsulfonyl ﬂuoride was added. As a probe for the gel
retardation assay, an oligonucleotide containing the Igj-chain binding
site (jB, 5 0-CCGGTTAACAGAGGGGGCTTTCCGAG-3 0) was syn-
thesized. The two complementary strands were annealed and labeled
with (a-32P)dCTP. Labeled oligonucleotides (10,000 cpm), 12 lg of nu-
clear extracts, and binding buﬀer [10 mM Tris–HCl, pH 7.6, 500 mM
KCl, 10 mM EDTA, 50% glycerol, 100 ng of poly (dIdC), and 1 mM
DTT] were incubated for 30 min at room temperature in a ﬁnal volume
of 20 ll. The reaction mixture was analyzed by electrophoresis on a 5%
polyacrylamide gel in 0.5· Tris–borate buﬀer. Speciﬁc binding was
controlled by competition with a 50-fold excess of cold jB or cAMP
response element (CRE) oligonucleotide.
2.6. Real-time RT-PCR
Cells were cultured to 60–80% conﬂuence in 60 mm dishes. RNA
was prepared as previously described [21,22]. Reverse transcription
was performed using 50 ng of total RNA in a 10 ll reaction mixture
(Promega, Madison, WI), containing oligo(dT) and avian myeloblasto-
sis virus reverse transcriptase. PCR was performed on the Roter-Gene
3000 System (Corbett Research, Morklake, Australia) using the SYBR
Green PCR Master Mix Reagent Kit (Qiagen, Valencia, CA). The
primers used are as follows: human VEGF; 5 0-GCAGAATCATCAC-
GAAGTGG-3 0 and 5 0-GCAACGCGAGTCTGTGTTTTTG-3 0, and
b-actin; 5 0-CTGAAGTCACCCATTGAACATGGC-30 and 5 0-
CAGAGCAGTAATCTCCTTCTGCAT-30. The relative levels of
VEGF mRNA were calculated using the standard curve generated
from cDNA dilutions. The mean cycle threshold (Ct) values from qua-
druplicate measurements were used to calculate gene expression, with
normalization to b-actin as an internal control. Calculations of the rel-
ative level of gene expression were conducted with the complementary
computer software (Corbett Research) using a standard curve. cDNA,
ampliﬁed by PCR (Perkin–Elmer System 2400, Norwalk, CT), was
visualized after staining with ethidium bromide.2.7. Quantitation of cytokines by ELISA
The quantitative determination of cytokines in culture supernatants
was performed by ELISA according to the manufacturer’s instruc-
tions. Culture supernatants were collected from cells 8 h after treat-
ment with PAF.2.8. Transient expression assay
Plasmid DNA was prepared using commercial kits (QIAGEN,
Chatsworth, CA). ECV304 cells were cultured to 60–80% conﬂuence
in 24-well plates. For each well, each plasmid DNA and 1 ll of Lipo-
fectAMINE reagent (Life Technologies, Inc., Gaithersburg, MD) were
separately diluted in 100 ll of Opti-MEM reduced serum medium (Life
Technologies, Inc.), mixed together, and incubated at room tempera-
ture for 1 h. Plates were then washed with serum-free medium,
200 ll of Opti-MEM reduced serum medium was added, and the di-
luted solution was added to the cells. Plates were incubated at 37 C
for 8 h, after which time growth medium containing 10% serum was
added. After additional 16 h incubation, cells were then left untreated
or were treated with 2 lM PAF for 8 h. Cell extracts were prepared
using passive lysis buﬀer. Luciferase assays were performed with the
Lumat LB9501 luminometer (Berthold, Germany). Luciferase activity
was normalized to b-galactosidase activity as an internal control. All
experiments were repeated at least three times with two diﬀerent
batches of puriﬁed DNA.
2.9. Statistical analysis
Data are represented as the mean ± S.E. Statistical signiﬁcance was
assessed by the Student’s t-test when two data sets were analyzed, or
by ANOVA followed by the appropriate post hoc test for multiple
data sets using the StatView statistical software package (version
4.5). All experiments were conducted at least twice. Reproducible re-
sults were obtained and representative data were, therefore, shown in
the ﬁgures.3. Results
3.1. PAF enhances VEGF expression through the activation of
NF-jB
We ﬁrst examined the role of PAF in VEGF promoter
activation, mRNA expression, and protein synthesis
in vitro. Treatment of ECV304 cells with PAF resulted in
VEGF promoter activation in a dose-dependent manner,
which was blocked by the PAF antagonist, WEB2170, the
NF-jB inhibitor, parthenolide, or cotransfection with IjBa
(Fig. 1A). Furthermore, PAF enhanced VEGF mRNA
expression (Fig. 1B) and protein synthesis (Fig. 1C), which
were blocked by WEB2170, parthenolide, cotransfection of
the cells with IjBa, or p65 AS, but not by a p65 NS
(Fig. 1B and C). We conﬁrmed the knockdown of NF-jB
p65 protein by Western blotting using an antibody against
the p65 subunit of NF-jB (data not shown). Cotransfection
of the cells with plasmids expressing p65 and p50 subunits of
NF-jB increased the luciferase activity (Fig. 2A), as well as
VEGF mRNA expression (Fig. 2B), both of which were
blocked by parthenolide or cotransfection of the cells with
IjBa. To complete the data of Fig. 2, the same experiments
were performed in DLD-1 cells that lack p53 activity due to
a point missense mutation (Cﬁ T, Ser-241ﬁ Phe) [36]. We
obtained similar patterns of luciferase activity (Fig. 2C)
and VEGF mRNA expression (Fig. 2D) as seen in Fig. 2A
and B. We conﬁrmed that the transfected p65, p50, IjBa
plasmids are expressing equivalent amounts of protein by
Western blotting (data not shown). These data indicate that
NF-jB activity is involved in PAF-induced VEGF expres-
sion.
Fig. 1. PAF enhances VEGF expression through the activation of NF-jB. (A) ECV304 cells (1 · 105/ml) were transfected with 0.5 lg VEGF-Luc
and/or 0.2 lg IjBa expression vector. The total concentration of DNA was adjusted to 1 lg per transfection with an empty vector. The PAF
antagonist, WEB2170 (WEB, 10 lg/ml), or the NF-jB inhibitor, parthenolide (Parthe, 5 lM), was added 30 min prior to PAF treatment. VEGF
promoter activity was assayed 8 h after PAF treatment, as described in Section 2. Luciferase activity was normalized by b-galactosidase activity to
determine transfection eﬃciency. All promoter activities are shown as fold activation relative to control. (B and C) Cells (4 · 105/ml) were incubated
with WEB2170 or parthenolide, 30 min prior to 2 lM PAF treatment, or transfected with IjBa expression vector, 12 h prior to PAF treatment.
ECV304 cells (5 · 104/ml) were incubated with p65 AS or p65 NS (1 lM) 5 days prior to PAF treatment. (B) RNA was isolated 4 h after PAF
treatment. Real-time RT-PCR was performed, as described in Section 2. The results of agarose gel electrophoresis of RT-PCR are shown (inset), as
are the combined quantitative analysis results by real-time RT-PCR. (C) VEGF protein was analyzed by ELISA in the culture supernatants collected
8 h after PAF treatment. *, P < 0.0001 compared with the control group; #, 0.0001 < P < 0.001 compared with the 2 lM PAF-treated group. Values
are expressed as mean ± S.E.
Fig. 2. NF-jB increases VEGF promoter activity and mRNA expression. 5 · 104 ECV304 cells (A) and DLD-1 cells (C) were cotransfected with
VEGF-Luc (0.5 lg) and NF-jB subunits (0.2 lg p65 and/or 0.1 lg p50) and/or increasing amounts (0.1 or 0.2 lg) of IjBa expression vector. The NF-
jB inhibitor, parthenolide (Parthe, 5 lM), was added 8 h prior to luciferase assay. VEGF promoter activity was assayed, as described in the legend
for Fig. 1. 8 · 105 ECV304 cells (B) and DLD-1 cells (D) were transfected with NF-jB subunits and/or IjBa expression vector. Real-time RT-PCR
was performed, as described in the legend for Fig. 1. *, P < 0.0001 compared with the control group; §, P < 0.0001 compared with the NF-jB subunits
(p65 and p50)-transfected group. Values are expressed as mean ± S.E.
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to PAF
The interaction between NF-jB and p53 pathways was ana-
lyzed using ECV304 cells cotransfected with NF-jB subunits
(p50 and p65), p53 (wild or mutated type) and reporter plas-
mids containing either TNF-a or p53RE promoter. p65/p50
expression increased TNF-a luciferase activity ﬁvefold, which
could be completely inhibited by wild-type, but not mutant,
p53 (Fig. 3A). Similar results were obtained in DLD-1 cells
(data not shown). Likewise, the p53-mediated increase of
p53RE luciferase activity was completely inhibited by co-
expression of the NF-jB subunits (Fig. 3B). However, cotrans-
fection with IjBa reversed the luciferase activity of the NF-jB
subunits in a dose-dependent manner (Fig. 3B). We next com-
pared the capacity of PAF to induce NF-jB activation in cells
with diﬀerent levels of p53 activity. Treatment of ECV304 cells
with PAF activated NF-jB, but not in p53-transfected
ECV304 cells (Fig. 3C). Likewise, PAF induced signiﬁcant
NF-jB activation in DLD-1 cells. However, PAF failed to in-
duce NF-jB activation in p53-transfected DLD-1 cellsFig. 3. Cross-talk exists between NF-jB and p53 in response to PAF. (A) EC
p50 (0.2 lg/0.1 lg), 0.2 lg wild-type (wt) p53, or mutant (mt) p53 expression
of p53RE-Luc, wild-type p53, NF-jB subunit (p65 and p50) expression vecto
The NF-jB inhibitor, parthenolide (Parthe, 5 lM), was added 8 h prior to
legend for Fig. 1. *, P < 0.0001 compared with the control group; §, P < 0.000
, P < 0.0001 compared with the wild-type p53-transfected group. , P < 0.0
Values are expressed as mean ± S.E. ECV304 cells (C) and DLD-1 cells (D)
with 2 lM PAF for 1 h. The nuclear extracts were incubated with a 32P-labe(Fig. 3D) indicating that a cross-regulation occurs between
NF-jB and p53 in ECV304 cells.
3.3. Decreased p53 activity is associated with a PAF-induced
increase of VEGF expression
We next examined whether PAF-induced inhibition of p53
activity is associated with an increase in VEGF production.
ECV 304 cells were cotransfected with a wild-type p53 expres-
sion vector and a p53RE promoter reporter. PAF treatment
signiﬁcantly inhibited p53 promoter activity (Fig. 4A, inset),
and the wild-type p53-induced increases in luciferase activity
(Fig. 4A). PAF signiﬁcantly increased the luciferase activity
when ECV304 cells were transfected with the VEGF luciferase
reporter. Wild-type p53 completely blocked the PAF eﬀect,
whereas the mutant form did not (Fig. 4B). Parallel to VEGF
luciferase activity, VEGF mRNA expression was similarly reg-
ulated by PAF and wild-type p53 (Fig. 4C). PAF increased
VEGF mRNA expression in DLD-1 cells, whereas PAF did
not show such an eﬀect in p53-transfected DLD-1 cells
(Fig. 4D). These data suggest that the level of p53 activityV304 cells (1 · 105/ml) were cotransfected with plasmid expressing p65/
vector and 0.5 lg TNF-a-Luc. (B) Cells were cotransfected with 0.1 lg
rs, and/or increasing amounts (0.1 or 0.2 lg) of IjBa expression vector.
luciferase assay. Luciferase assay was performed, as described in the
1 compared with the NF-jB subunits (p65 and p50)-transfected group;
001 compared with the NF-jB subunits and p53-cotransfected group.
were transfected with 0.2 lg wild-type p53 or mutant p53 and treated
led jB, and electrophoresed on a 5% polyacrylamide gel.
Fig. 4. PAF enhances VEGF expression by inhibiting p53 activity. (A) ECV304 cells (1 · 105/ml) were cotransfected with 0.1 lg p53RE-Luc and
0.2 lg wild-type p53 or mutant p53 expression vector, and then treated with the indicated concentrations of PAF. (Inset) Cells were transfected with
0.1 lg p53RE-Luc and treated with 2 lM PAF. (B) ECV304 cells were cotransfected with 0.5 lg VEGF-Luc and wild-type p53 (0.1 or 0.2 lg) or
mutant p53 (0.2 lg) expression vector. ECV304 cells (C) and DLD-1 cells (D) were transfected with 0.2 lg wild-type p53 or mutant p53 and treated
with 2 lM PAF. Luciferase assay and real-time RT-PCR were performed, as described in the legend for Fig. 1. *, P < 0.001 compared with the
control group; , P < 0.001 compared with the wild-type p53-transfected group; #, P < 0.0001 compared with the PAF-treated group. Values are
expressed as mean ± S.E.
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are inversely correlated.4. Discussion
Despite the fact that the VEGF promoter does not contain
an NF-jB binding site [7], we and others have reported that
VEGF production and gene expression are inhibited by NF-
jB inhibition [21–23], suggesting that NF-jB enhances VEGF
expression indirectly. In this study, we investigated the mecha-
nisms underlying NF-jB-dependency in PAF-induced VEGF
expression and demonstrated that NF-jB activation by PAF
results in p53 inactivation, which in turn leads to VEGF
expression.
Our results show that a mutually exclusive activation of NF-
jB and p53 exists in response to PAF. Such a conclusion is
supported by the ﬁndings that (i) p65/p50 expression increased
TNF-a promoter activity, which was completely inhibited by
wild-type p53, and (ii) the p53-mediated increase in p53RE
promoter activity was completely inhibited by the expression
of the NF-jB p50 or p65 subunits. These data are consistent
with the ﬁndings of several studies showing mutual transcrip-
tional interference between NF-jB and p53 [6,29–33]. Further-more, we demonstrated that the interaction between these two
factors also occurred in PAF-treated ECV304 cells, suggesting
that downregulation of p53 activity through an interaction
with NF-jB is a key process in PAF-induced VEGF synthesis.
The mechanism underlying mutual regulation is controver-
sial; both NF-jB and p53 interact with the transcriptional
coactivator protein p300 and CREB-binding protein, so both
factors may be competing for a limited pool of transactivators
[31]. However, inactivation of p53 by the viral transcriptional
activator protein Tax is dependent upon NF-jB activity, but
not p300 binding or CREB transactivation [33], and the direct
interaction between these two transcriptional factors is medi-
ated by their dimerization/tetramerization [37]. Whatever the
mechanism for NF-jB and p53 interaction, we here demon-
strate for the ﬁrst time that the mutual interaction between
these two proteins appears to play a key role in PAF-induced
angiogenesis.
We also demonstrated that PAF-induced inhibition of p53
activity results in an increase of VEGF production. PAF treat-
ment of ECV304 cells cotransfected with a wild-type p53
expression vector and a VEGF promoter reporter increased
VEGF luciferase activity and VEGF mRNA expression.
PAF also increased VEGF mRNA expression in DLD-1 cells
with no p53 activity. How can p53 regulate VEGF expression?
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binding sites [7,8], and p53 forms a complex with SP-1 to pre-
vent binding to the VEGF promoter [38]. In addition, overex-
pression of wild-type of p53 reduces VEGF production in
HeLa cells through competition between p53 and the AP-1 fac-
tor, c-Jun [39]. This competitive inhibition may explain how
p53 can inhibit VEGF production despite no binding site in
the VEGF promoter. Further studies are required to address
whether the same competitive inhibition regulates VEGF
expression by PAF.
In summary, we demonstrated that NF-jB and p53 cross-
regulation is critical for PAF-induced VEGF expression.
PAF may induce NF-jB activation, which in turn downregu-
lates p53 activity, resulting in enhancement of VEGF expres-
sion. Given that PAF is the proximal mediator in a variety
of inﬂammatory reactions and a potent angiogenic factor,
our data provides evidence to better understand the role of
PAF in physiological as well as pathological angiogenesis.
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